Nigericin causes triple-negative breast cancer cell death by inducing concurrent caspase-1/GSDMD-mediated pyroptosis and promoting the infiltration and activation of T cells, making it a promising antitumour agent, especially when combined with anti-PD-1 antibody treatment [35]. The gene discussed is CASP1; the disease is triple-negative breast carcinoma.